Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Diamyd Medical

9.88 SEK

-0.20 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.20 %
-6.08 %
-16.84 %
0.00 %
-39.62 %
-32.48 %
-36.30 %
-67.52 %
+229.04 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
1.36B SEK
Turnover
2.26M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.1
2026

Interim report Q1'26

25.3
2026

Interim report Q2'26

24.6
2026

Interim report Q3'26

All
Press releases
ShowingAll content types
Regulatory press release12 hours ago

Bulletin from Annual General Meeting of Diamyd Medical AB

Diamyd Medical
Regulatory press release12/2/2025, 9:55 AM

Diamyd Medical AB: Annual Report 2024/2025

Diamyd Medical
Press release12/1/2025, 6:41 AM

BioStock: Lif's sustainability conference 2025 with a focus on transition, competitiveness and sustainable production

Diamyd Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/14/2025, 7:45 AM

Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026

Diamyd Medical
Regulatory press release11/13/2025, 7:28 AM

Diamyd Medical AB: Information about the Annual Report 2024/2025

Diamyd Medical
Regulatory press release11/12/2025, 11:45 AM

Diamyd Medical AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment

Diamyd Medical
Press release10/10/2025, 10:16 AM

BioStock: Screening - a potential game changer for type 1 diabetes

Diamyd Medical
Press release10/9/2025, 5:27 AM

DNB Carnegie Access: Diamyd Medical: Solid finish to the fiscal year

Diamyd Medical
Regulatory press release10/8/2025, 6:15 AM

Diamyd Medical AB: Year-End Report 24/25

Diamyd Medical
Regulatory press release10/3/2025, 12:40 PM

Diamyd Medical AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes

Diamyd Medical
Press release9/25/2025, 9:36 AM

BioStock: Video from Diamyd Medical's presentation at BioStock Investing in Life Science – From Seed to Success

Diamyd Medical
Regulatory press release9/11/2025, 8:00 AM

Diamyd Medical AB: New analysis to be presented at EASD supports potential of Diamyd[®] to delay the progression of Stage 3 Type 1 Diabetes

Diamyd Medical
Regulatory press release9/10/2025, 7:00 AM

Diamyd Medical AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes

Diamyd Medical
Regulatory press release9/5/2025, 11:00 AM

Diamyd Medical AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference

Diamyd Medical
Press release9/3/2025, 4:18 AM

DNB Carnegie Access: Diamyd Medical: DNB Carnegie’s Micro & Small Cap Day 2025 – highlights

Diamyd Medical
Regulatory press release7/22/2025, 2:00 PM

Diamyd Medical AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June

Diamyd Medical
Press release7/1/2025, 9:44 AM

DNB Carnegie Access: Diamyd Medical: Progress towards key catalyst in March 2026 – Q3 review

Diamyd Medical
Press release7/1/2025, 8:00 AM

DNB Carnegie Access: Diamyd Medical: Intervju - Närmar sig viktiga studiedata

Diamyd Medical
Regulatory press release6/25/2025, 6:15 AM

Diamyd Medical AB: Quarterly Report 3 24/25

Diamyd Medical
Regulatory press release6/16/2025, 1:05 PM

Diamyd Medical AB: Diamyd Medical to participate in two key US diabetes events

Diamyd Medical
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.